MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells

mTOR activation leads to enhanced survival signaling in acute myeloid leukemia (AML) cells. The active-site mTOR inhibitors (asTORi) represent a promising new approach to targeting mTOR in AKT/mTOR signaling. MLN0128 is an orally-administered, second-generation asTORi, currently in clinical developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Zhihong, Wang, Rui-Yu, Qiu, Yi Hua, Mak, Duncan H., Coombes, Kevin, Yoo, Suk Young, Zhang, Qi, Jessen, Katti, Liu, Yi, Rommel, Christian, Fruman, David A., Kantarjian, Hagop M., Kornblau, Steven M., Andreeff, Michael, Konopleva, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342403/
https://www.ncbi.nlm.nih.gov/pubmed/27391151
http://dx.doi.org/10.18632/oncotarget.10397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342403/
https://www.ncbi.nlm.nih.gov/pubmed/27391151
http://dx.doi.org/10.18632/oncotarget.10397

Ejemplares similares